Myeloma Video Channel
Explore the latest insights and summaries from experts in Myeloma.
Recommended for You
Loading...
Trending Videos This Week
Loading...
Treatment Landscape
2024 ASCO® Annual Meeting Insights Hub
Highlights of Recent Updates in Myeloma: Part 1 - Frontline Treatment
FEATURING
Andrzej Jakubowiak
- 307 views
- July 31, 2024
- 3
2024 ASCO® Annual Meeting Insights Hub
Highlights of Recent Updates in Myeloma: Part 2 - R/R Treatment
FEATURING
Andrzej Jakubowiak
- 256 views
- July 31, 2024
- 2
Dana-Farber Cancer Institute
Advances in Multiple Myeloma 2024: From Bench to Bedside
FEATURING
Kenneth Anderson
- 641 views
- July 1, 2024
- 5
Insights from 2024 EHA Annual Meeting
Highlights in Plasma Cell Disorders From ASCO® and EHA
FEATURING
Samer Al Hadidi
- 471 views
- June 27, 2024
- 7
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Treatment Strategies for R/R Multiple Myeloma
FEATURING
Claudio Cerchione
- 29 views
- September 6, 2024
MyCancerHaven
Experts Discuss How They Manage MM in the Elderly
FEATURING
Ravi Vij,
Sascha Tuchman
- 36 views
- August 30, 2024
- 1
MyCancerHaven
Isatuximab in 1L Transplant-Ineligible Myeloma
FEATURING
Ravi Vij,
Adriana Rossi
- 29 views
- August 30, 2024
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Summary: "The Best of Myeloma - Review of the Top 5 Abstracts"
FEATURING
Hamza Hashmi
- 621 views
- July 1, 2024
- 5
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Treatment of 1L Myeloma in 2024
FEATURING
Ahmad Ibrahim
- 34 views
- August 26, 2024
Insights from 2024 EHA Annual Meeting
Highlights in Plasma Cell Disorders From ASCO® and EHA
FEATURING
Samer Al Hadidi
- 471 views
- June 27, 2024
- 7
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Sequencing Immunotherapies and CAR-T Application in Multiple Myeloma
FEATURING
Claudio Cerchione
- 36 views
- September 6, 2024
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Summary: "Quadruplets in NDMM - The More the Better?"
FEATURING
Ola Landgren
- 414 views
- June 12, 2024
- 7
Dana-Farber Cancer Institute
Advances in Multiple Myeloma 2024: From Bench to Bedside
FEATURING
Kenneth Anderson
- 641 views
- July 1, 2024
- 5
SOHO Brazil 2024
When to Consider Bispecific and CAR-T Therapy in MM
FEATURING
Noopur S. Raje
- 401 views
- July 11, 2024
- 5
2024 ASCO® Annual Meeting Insights Hub
Highlights of Recent Updates in Myeloma: Part 1 - Frontline Treatment
FEATURING
Andrzej Jakubowiak
- 307 views
- July 31, 2024
- 3
Dana-Farber Cancer Institute
CAR T-Cells in Multiple Myeloma in 2024
FEATURING
Adam Sperling
- 268 views
- July 2, 2024
- 4
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "Sequencing Immunotherapy for Myeloma"
FEATURING
Samir Parekh
- 245 views
- June 25, 2024
- 4
2024 ASCO® Annual Meeting Insights Hub
Highlights of Recent Updates in Myeloma: Part 2 - R/R Treatment
FEATURING
Andrzej Jakubowiak
- 256 views
- July 31, 2024
- 2
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "Indirect Comparison of Linvoseltamab Vs. Teclistamab for Triple-Class Exposed R/R MM"
FEATURING
Sundar Jagannath
- 183 views
- June 17, 2024
- 2
ecancer
ASCO® 2024 Summary: "IMROZ & BENEFIT Studies in Newly Diagnosed Myeloma"
FEATURING
Xavier Leleu
- 182 views
- June 24, 2024
- 1
Total Health
Hematologic Malignancies Update: Treatment Strategies for AML, DLBCL, MM, and CLL
FEATURING
Marcello Maria Rotta
- 240 views
- July 8, 2024
Integrity CE
Treatment Strategies for R/R MM After Frontline Anti-CD38 Therapy
FEATURING
Saad Usmani,
Jens Hillengass
- 213 views
- August 13, 2024
- 2
Rush University Medical Center
CAR-T vs. Bispecific Antibodies in R/R MM: Insights and Future Directions
FEATURING
Attaya Suvannasankha
- 195 views
- June 14, 2024
- 2
UCSF School of Medicine
Best of ASCO® 2024: Myeloma Highlights and Practice Impacts
FEATURING
Ajai Chari
- 171 views
- August 7, 2024
- 2
Dana-Farber Cancer Institute
Continued Evolution of Therapy for Patients With Newly Diagnosed MM
FEATURING
Clifton Mo
- 144 views
- June 10, 2024
- 2
Dickran Kazandjian
Overall Survival in Newly Diagnosed, Transplant-Ineligible MM: Results From MAIA
- 139 views
- August 9, 2024
Rush University Medical Center
High-Risk Myeloma: Updates in Defining and Managing
FEATURING
Jeffrey Zonder
- 133 views
- June 6, 2024
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "Real World Outcomes of Pts With MM Who Received Bispecific Antibodies After CAR-T"
FEATURING
Radhika Bansal
- 130 views
- June 19, 2024
ecancer
EHA 2024 Summary: Highlights of Key Studies in Multiple Myeloma
FEATURING
Claudio Cerchione
- 112 views
- July 23, 2024
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: Sequential Administration of Bispecific Antibodies and Anti-BCMA CAR-T in R/R MM
FEATURING
David Fandrei
- 117 views
- June 30, 2024
ecancer
ASCO® 2024 Insights: "IMROZ - A Ph3 Study of Isatuximab + VRd vs. VRd for Transplant-Ineligible NDMM"
FEATURING
Thierry Facon
- 109 views
- June 24, 2024
COR2ED The Heart of Medical Education
Optimizing the Management of Multiple Myeloma in the Early R/R Setting
- 100 views
- July 11, 2024
Integrity CE
Current Updates in the Management of NDMM
FEATURING
Jens Hillengass,
Saad Usmani
- 81 views
- August 15, 2024
Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course
Multiple Myeloma: Not as Simple as "CRAB" Anymore
FEATURING
Rahul Banerjee
- 410 views
- August 14, 2024
- 4
ecancer
ASCO® 2024 Insights: "Importance of MRD in Newly Diagnosed Multiple Myeloma"
FEATURING
Xavier Leleu
- 78 views
- July 18, 2024
- 1
SOHO Brazil 2024
Frontline MM: Are Four Better Than Three?
FEATURING
Noopur S. Raje
- 79 views
- July 11, 2024
- 1
Nebraska Oncology Society
Updates on Advances in the Treatment of Newly Diagnosed Myeloma
FEATURING
Ravi Vij
- 84 views
- August 1, 2024
- 2
ecancer
ASCO® 2024 Insights: "PERSEUS Trial - MRD Analysis of Dara + VRd in Transplant-Eligible NDMM"
FEATURING
Paula Rodríguez-Otero
- 64 views
- June 24, 2024
- 1
UChicago Medicine Annual Practice Updates in Hematology and Oncology
UChicago Medicine Best of ASCO® 2024: Myeloma
FEATURING
Jennifer Cooperrider
- 87 views
- September 4, 2024
James Essell
Bringing CAR-T for Hematologic Malignancies to the Community Practices
- 59 views
- June 20, 2024
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "New Agents on the Horizon in NHL and Myeloma - Targets Other Than CD3/CD20, New Constructs, and Trispecifics"
FEATURING
Paolo Strati
- 47 views
- June 12, 2024
MyCancerHaven
Experts Discuss How They Plan to Use CAR-T in Myeloma After First Relapse
FEATURING
Ravi Vij,
Al-Ola Abdallah
- 71 views
- August 30, 2024
Meral Beksaç
Post ASCO®/EHA 2024 Treatment of Transplant Ineligible Myeloma Patients
- 39 views
- July 22, 2024
Dana-Farber Cancer Institute
Bispecific Antibody Therapy in Multiple Myeloma
FEATURING
Shonali Midha
- 58 views
- July 1, 2024
Nebraska Oncology Society
Updates on Advances in the Treatment R/R Myeloma
FEATURING
Ravi Vij
- 73 views
- August 1, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Management of Smoldering Myeloma
FEATURING
Claudio Cerchione
- 61 views
- August 27, 2024
- 1
Houston Methodist
Multiple Myeloma: A Journey From Pharaoh's Times to 2024
FEATURING
Siddhartha Ganguly
- 144 views
- September 10, 2024
- 2
MyCancerHaven
Experts Discuss the Future of Personalized Therapy in Myeloma
FEATURING
Ravi Vij,
Kenneth Shain
- 22 views
- August 30, 2024
Indy Hematology Review
2024 Updates on Emerging & Current Treatment of Multiple Myeloma
FEATURING
Kenneth Anderson
- 1,211 views
- April 16, 2024
- 5
Indy Hematology Review
HSCT in 2024: What Every Hematologist Needs to Know
FEATURING
Richard Childs
- 745 views
- April 18, 2024
- 5
Indy Hematology Review
Managing Newly Diagnosed MM in 2024
FEATURING
Saad Usmani
- 686 views
- May 2, 2024
- 5
Scripps Health
Should Patients With High-Risk SMM Be Treated Outside a Clinical Trial? No
FEATURING
Morie Gertz
- 527 views
- March 29, 2024
- 5
MyCancerHaven
Will CAR-Ts and Bispecifics Replace HSCT in Myeloma?
FEATURING
Ravi Vij,
Samer Al Hadidi
- 622 views
- May 23, 2024
- 5
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Will Immune Therapy Replace Transplant in Hematologic Malignancies?
FEATURING
Robert Peter Gale
- 508 views
- February 21, 2024
- 2
University of Colorado Division of Hematology
2024 Updates on Multiple Myeloma Treatment
FEATURING
Daniel Sherbenou
- 430 views
- April 11, 2024
- 1
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient
Managing Newly Diagnosed Myeloma in 2024
FEATURING
Alfred Garfall
- 428 views
- March 11, 2024
- 1
Saurabh Chhabra
Bispecifics & CAR-Ts in MM: How to Choose and How to Sequence
- 382 views
- April 19, 2024
- 2
Moffitt Cancer Center
Multiple Myeloma: What You Need to Know About New FDA Approvals of CAR-Ts in Earlier Lines
FEATURING
Doris Hansen
- 375 views
- April 15, 2024
- 2
SOHO Highlights: State of the Art and Next Questions
State of the Art and Next Questions: Multiple Myeloma
FEATURING
Sagar Lonial
- 307 views
- March 25, 2024
Total Health
Multiple Myeloma: A New Risk-Adapted Approach
FEATURING
Jason Chandler
- 278 views
- February 23, 2024
- 1
City of Hope
Practical Perspectives on Recent CAR-T FDA Approvals in Myeloma
FEATURING
Murali Janakiram
- 288 views
- April 26, 2024
- 3
Moffitt Cancer Center
State-of-the-Art: Bispecific Antibodies in Myeloma - Which? How? When?
FEATURING
Ariel Grajales-Cruz
- 267 views
- March 4, 2024
- 6
Winship Cancer Institute - Emory University
Multiple Myeloma: Clinical Challenges for the Community Clinician
FEATURING
Nisha Joseph
- 257 views
- April 16, 2024
- 3
MyCancerHaven
Multiple Myeloma: Experts Discuss How to Choose Between CAR-Ts and Bispecifics
FEATURING
Ravi Vij,
Nitya Nathwani
- 260 views
- May 2, 2024
- 2
MyCancerHaven
Experts Discuss Current Approaches in Triple Class Refractory MM
- 272 views
- February 20, 2024
- 2
Indy Hematology Review
Multiple Myeloma: Understanding Your Immune Effector Therapeutic Options
FEATURING
Saad Usmani
- 230 views
- April 18, 2024
- 2
Indy Hematology Review
2024 Updates on Understanding & Managing Immune Effector Cell Toxicities in Hematologic Malignancies
FEATURING
David Reeves
- 237 views
- April 30, 2024
- 2
Lucio Gordan
TAURUS Study: Chart Review of DRd vs. VRd in Transplant-Ineligible Patients With NDMM
- 199 views
- April 26, 2024
- 1
UChicago Medicine
Multiple Myeloma: CAR T-Cells and Bispecifics - A Case for Moving Them Early
FEATURING
Noopur Raje
- 251 views
- March 18, 2024
- 1
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient
2024 Updates in MM: The Role of Immunotherapy
FEATURING
Adam D. Cohen
- 284 views
- March 1, 2024
- 4
Moffitt Cancer Center
Newly Diagnosed Myeloma: Why We Should NOT Use a Response-Adapted Approach to Transplant
FEATURING
Omar Castañeda-Puglianini
- 192 views
- March 11, 2024
- 1
Oncology Data Advisor
Venetoclax for Multiple Myeloma in the Post-CANOVA Era
FEATURING
Rahul Banerjee,
Andrew Yee
- 180 views
- January 8, 2024
Insights from 2023 ASH Annual Meeting
RRMM: Effects of Ide-Cel vs. Standard Regimens on HRQoL in Patients Who Had Received 2-4 Prior Regimens - Updated Results From KarMMa-3
FEATURING
Michel Delforge
- 174 views
- January 8, 2024
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
How I Treat R/R MM With CAR-T and Bispecific Antibodies
FEATURING
Claudio Cerchione
- 160 views
- February 15, 2024
GRACE
A Summary of Efficacy and Safety Data From Bispecific Antibodies in Myeloma
FEATURING
Sridevi Rajeeve
- 149 views
- March 6, 2024
- 1
Insights from 2023 ASH Annual Meeting
Triple-Class-Exposed R/R MM: Results From the KarMMa-3 Trial of Ide-Cel vs. Standard Regimens
FEATURING
Krina Patel
- 185 views
- February 12, 2024
- 1
Louisville Hematology Highlights
Updates on the Progress in Multiple Myeloma
FEATURING
Donna Reece
- 146 views
- February 26, 2024
- 2
Saurabh Chhabra
BCMA-Directed Bispecifics in MM: Clinical Data & Guidelines for AE Management
- 147 views
- May 21, 2024
- 1
Memorial Sloan Kettering Cancer Center
ASTCT Survey on Management of R/R Myeloma Patients After Failure by CAR-T
FEATURING
Hamza Hashmi
- 142 views
- May 21, 2024
- 1
UChicago Medicine
Practice-Changing and Promising New Treatments in Myeloma
FEATURING
Ben Derman
- 135 views
- March 19, 2024
Yale Cancer Center
Frontline Treatment Strategies in MM: A Comprehensive Overview of Clinical Trials and Real-World Data
FEATURING
Terri Parker
- 118 views
- May 14, 2024
- 1
Moffitt Cancer Center
Hot Off the Press: Experts Discuss the Latest Data in Plasma Cell Dyscrasias
- 117 views
- March 6, 2024
GRACE
Oncologists' Guidance on Treating Smoldering Myeloma: Panel Discussion
- 133 views
- March 15, 2024
Dana-Farber Cancer Institute
Updates in the Management of SMM/MGUS and the Prevention of Progression
FEATURING
Yuxin Liu
- 90 views
- July 2, 2024
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
How I Manage Late Relapsed Myeloma With T-Cell Engaging Therapy
FEATURING
Alessandra Romano
- 14 views
- February 15, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Overview of R/R Multiple Myeloma and Data on Carfilzomib
FEATURING
Tulin Tuglular
- 15 views
- September 11, 2024
Therapeutic Agents
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "DREAMM-7 Trial - BelamafVd vs. DaraVd in R/R MM"
FEATURING
Maria-Victoria Mateos
- 288 views
- June 6, 2024
- 1
MyCancerHaven
Isatuximab in 1L Transplant-Ineligible Myeloma
FEATURING
Ravi Vij,
Adriana Rossi
- 29 views
- August 30, 2024
SOHO Brazil 2024
Managing Infectious Complications With Bispecific and CAR-T Therapy in MM
FEATURING
Noopur S. Raje
- 193 views
- July 11, 2024
- 2
MyCancerHaven
Will CAR-Ts and Bispecifics Replace HSCT in Myeloma?
FEATURING
Ravi Vij,
Samer Al Hadidi
- 622 views
- May 23, 2024
- 5
Insights from 2024 EHA Annual Meeting
Highlights in Plasma Cell Disorders From ASCO® and EHA
FEATURING
Samer Al Hadidi
- 471 views
- June 27, 2024
- 7
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Summary: "Comparative Review of Toxicities and Their Management With Bispecific Agents in MM and B-Cell NHL"
FEATURING
Monique Minnema
- 283 views
- June 7, 2024
- 4
Dana-Farber Cancer Institute
CAR T-Cells in Multiple Myeloma in 2024
FEATURING
Adam Sperling
- 268 views
- July 2, 2024
- 4
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "Indirect Comparison of Linvoseltamab Vs. Teclistamab for Triple-Class Exposed R/R MM"
FEATURING
Sundar Jagannath
- 183 views
- June 17, 2024
- 2
Stanford Medicine
Risk of Second Malignancies and T-Cell Lymphoma After CAR T-Cell Therapy
FEATURING
Mark Hamilton
- 194 views
- June 28, 2024
- 3
ecancer
ASCO® 2024 Summary: "IMROZ & BENEFIT Studies in Newly Diagnosed Myeloma"
FEATURING
Xavier Leleu
- 182 views
- June 24, 2024
- 1
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "The BENEFIT Study - Isa-VRd vs. Isa-Rd for Transplant-Ineligible NDMM"
FEATURING
Xavier Leleu
- 155 views
- June 11, 2024
UCSF School of Medicine
Best of ASCO® 2024: Myeloma Highlights and Practice Impacts
FEATURING
Ajai Chari
- 171 views
- August 7, 2024
- 2
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Summary: "Current Status of Bispecific Antibody Therapy in R/R MM"
FEATURING
Meera Mohan
- 158 views
- June 16, 2024
- 1
Rush University Medical Center
BCMA & Beyond: Novel Targets for Immunotherapy in MM
FEATURING
Ben Derman
- 158 views
- June 14, 2024
- 2
Supratik Basu
How I Approach Switching to Daratumumab SC From IV in Patients With MM
- 118 views
- August 2, 2024
- 2
Dana-Farber Cancer Institute
Future of Novel Next Generation Therapy in the Management of R/R MM
FEATURING
Paul Richardson
- 218 views
- June 18, 2024
- 3
ecancer
ASCO® 2024 Insights: "CARTITUDE-4 Study - Benefits of Ciltacabtagene Autoleucel in Lenalidomide-Refractory Functional High-Risk MM"
FEATURING
Luciano Costa
- 109 views
- June 24, 2024
ecancer
ASCO® 2024 Insights: "IMROZ - A Ph3 Study of Isatuximab + VRd vs. VRd for Transplant-Ineligible NDMM"
FEATURING
Thierry Facon
- 109 views
- June 24, 2024
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: PERSEUS Trial MRD Analysis: Dara + VRd in Transplant-Eligible NDMM
FEATURING
Pieter Sonneveld
- 95 views
- June 20, 2024
ecancer
ASCO® 2024 Insights: "Results of Preliminary Safety & Efficacy of Belantamab Mafodotin and Elotuzumab in R/R MM"
FEATURING
Natalia Neparidze
- 73 views
- June 25, 2024
ecancer
ASCO® 2024 Insights: "MajesTEC-7 Study - Safety and Efficacy of Tec-DR in NDMM"
FEATURING
Salomon Manier
- 67 views
- June 26, 2024
ecancer
ASCO® 2024 Insights: "Importance of MRD in Newly Diagnosed Multiple Myeloma"
FEATURING
Xavier Leleu
- 78 views
- July 18, 2024
- 1
Nebraska Oncology Society
Therapeutic Potential of Bispecific Antibodies and BiTEs in Treating MM
FEATURING
Al-Ola Abdallah
- 61 views
- July 10, 2024
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: Results by Cytogenetic Risk From PERSEUS - Dara-VRd in Transplant-Eligible Newly Diagnosed MM
FEATURING
Meletios Dimopoulos
- 71 views
- July 5, 2024
- 1
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "New Agents on the Horizon in NHL and Myeloma - Targets Other Than CD3/CD20, New Constructs, and Trispecifics"
FEATURING
Paolo Strati
- 47 views
- June 12, 2024
MyCancerHaven
Experts Discuss How They Plan to Use CAR-T in Myeloma After First Relapse
FEATURING
Ravi Vij,
Al-Ola Abdallah
- 71 views
- August 30, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Current Overview of Biscpecific Antibodies in Hematologic Malignancies
FEATURING
Bahar Uncu Ulu
- 50 views
- August 15, 2024
Dana-Farber Cancer Institute
Bispecific Antibody Therapy in Multiple Myeloma
FEATURING
Shonali Midha
- 58 views
- July 1, 2024
MyCancerHaven
DreaMM-7 and DreaMM-8: Ready for the Return of Belamaf in Myeloma?
FEATURING
Ravi Vij,
Ajai Chari
- 98 views
- September 3, 2024
ecancer
EHA 2024 Insights: DREAMM-8 Trial Summary - Belamaf + PomDex Vs. Bortezomib + PomDex in R/R MM
FEATURING
Meletios Dimopoulos
- 32 views
- July 24, 2024
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: Infectious Complications in BCMA- and GPRC5D-Targeted Immunotherapy for MM
FEATURING
Julia Mersi
- 28 views
- July 2, 2024
ecancer
ASCO® 2024 Insights: "Long-Term Follow-Up of MajesTEC-1 Trial - Teclistamab in R/R MM"
FEATURING
Alfred Garfall
- 25 views
- June 20, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Current Status of Lenalidomide Maintenance in Myeloma
FEATURING
Ant Uzay
- 16 views
- August 15, 2024
MyCancerHaven
Isatuximab in 1L Transplant-Ineligible Myeloma
FEATURING
Ravi Vij,
Adriana Rossi
- 29 views
- August 30, 2024
Samer Al Hadidi
CAR-Ts Earlier in MyelomaTherapy?: What We Learned From the Recent FDA ODAC Meeting
- 600 views
- March 29, 2024
- 3
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient
Managing Newly Diagnosed Myeloma in 2024
FEATURING
Alfred Garfall
- 428 views
- March 11, 2024
- 1
Moffitt Cancer Center
State-of-the-Art: Bispecific Antibodies in Myeloma - Which? How? When?
FEATURING
Ariel Grajales-Cruz
- 267 views
- March 4, 2024
- 6
MyCancerHaven
Multiple Myeloma: Experts Discuss How to Choose Between CAR-Ts and Bispecifics
FEATURING
Ravi Vij,
Nitya Nathwani
- 260 views
- May 2, 2024
- 2
Indy Hematology Review
Multiple Myeloma: Understanding Your Immune Effector Therapeutic Options
FEATURING
Saad Usmani
- 230 views
- April 18, 2024
- 2
Indy Hematology Review
2024 Updates on Understanding & Managing Immune Effector Cell Toxicities in Hematologic Malignancies
FEATURING
David Reeves
- 237 views
- April 30, 2024
- 2
Moffitt Cancer Center
CAR T-Cell Therapies for Pts With R/R Myeloma: Updates From the Real World
FEATURING
Doris Hansen
- 244 views
- May 24, 2024
- 1
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient
2024 Updates in MM: The Role of Immunotherapy
FEATURING
Adam D. Cohen
- 284 views
- March 1, 2024
- 4
ecancer
PERSEUS Trial Summary: Adding Daratumumab to VRd as a Frontline Therapy for Newly Diagnosed MM
FEATURING
Pieter Sonneveld
- 193 views
- March 5, 2024
- 2
Insights from 2023 ASH Annual Meeting
RRMM: Effects of Ide-Cel vs. Standard Regimens on HRQoL in Patients Who Had Received 2-4 Prior Regimens - Updated Results From KarMMa-3
FEATURING
Michel Delforge
- 174 views
- January 8, 2024
Louisville Hematology Highlights
New Directions in CAR-T: Targeting Novel Antigens
FEATURING
Robert Emmons
- 146 views
- February 27, 2024
- 2
Saurabh Chhabra
BCMA-Directed Bispecifics in MM: Clinical Data & Guidelines for AE Management
- 147 views
- May 21, 2024
- 1
GRACE
Updates on Bispecific Antibodies in Myeloma
FEATURING
Sridevi Rajeeve
- 144 views
- February 15, 2024
- 2
Lucio Gordan
Impact of a Best Practices Program in Patients With R/R MM Receiving Selinexor
- 128 views
- April 8, 2024
- 1
GRACE
Overview on Current Immunotherapy Options in Myeloma
FEATURING
Sridevi Rajeeve
- 121 views
- February 15, 2024
- 1
Yale Cancer Center
Advances in CAR-Ts in Myeloma: Recent Research & Clinical Findings
FEATURING
Noffar Bar
- 106 views
- May 20, 2024
Insights from 2023 ASH Annual Meeting
High-Risk NDMM: KarMMa-2 Extended Follow-Up - Ide-Cel in HR-NDMM Patients With Inadequate Response to Frontline AutoSCT
FEATURING
Melissa Alsina
- 121 views
- January 24, 2024
Oncology Data Advisor
Lowering Talquetamab Dose Intensity to Improve Tolerability in MM - Results From MonumenTAL-1
FEATURING
Ajai Chari
- 92 views
- February 12, 2024
MyCancerHaven
Experts Discuss CELMoDs in MM: Current Data and Future Applications
- 89 views
- May 23, 2024
- 1
MyCancerHaven
Incorporating Selinexor Into the Myeloma Practice
FEATURING
Ravi Vij,
Cristina Gasparetto
- 83 views
- May 22, 2024
Icahn School of Medicine at Mount Sinai
AACR 2024 Insights: "Linvoseltamab, a BCMA-Targeted BsAb, in Pts With R/R Myeloma Including Difficult-to-Treat Subgroups"
FEATURING
Sundar Jagannath
- 64 views
- May 2, 2024
MyCancerHaven
How I Manage Myeloma Patients Long Term After Bispecific or CAR-T Therapy
FEATURING
Ravi Vij,
Binod Dhakal
- 66 views
- February 22, 2024
- 1
UChicago Medicine
CAR-Ts in Heme Malignancies: Practical Perspectives on Trials, Access, and Future Directions
- 33 views
- March 29, 2024
GRACE
The Future of Bispecific Antibodies in Myeloma
FEATURING
Sridevi Rajeeve
- 28 views
- March 6, 2024
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
IKEMA Trial Final Updates: Carfilzomib/Dex +/- Isatuximab in Patients With R/R MM
FEATURING
Ecenur Güder Arslan
- 26 views
- February 15, 2024
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
How I Manage Infections in Myeloma to Decrease Morbidity/Mortality
FEATURING
Ajai Chari
- 32 views
- February 16, 2024
COR2ED The Heart of Medical Education
Optimizing the Management of Multiple Myeloma in the Early R/R Setting
- 100 views
- July 11, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Overview of R/R Multiple Myeloma and Data on Carfilzomib
FEATURING
Tulin Tuglular
- 15 views
- September 11, 2024
Diagnostics & Biomarkers
Dana-Farber Cancer Institute
Multiple Myeloma 101: Diagnosis, Prognosis, and Risk
FEATURING
Paul Richardson
- 700 views
- July 2, 2024
- 5
Total Health
Multiple Myeloma: A New Risk-Adapted Approach
FEATURING
Jason Chandler
- 278 views
- February 23, 2024
- 1
MyCancerHaven
How I Use MRD in the Management of Multiple Myeloma
FEATURING
Ravi Vij,
Attaya Suvannasankha
- 214 views
- February 22, 2024
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "MRD2STOP Study - Discontinuation of Maintenance Therapy in MM Guided by Multimodal MRD Negativity"
FEATURING
Ben Derman
- 395 views
- June 11, 2024
- 3
i3 Health
MRD Testing in Leukemias: When Negativity Is a Positive Thing
FEATURING
Noopur S. Raje
- 471 views
- March 15, 2024
- 1
Dana-Farber Cancer Institute
Advances in Multiple Myeloma 2024: From Bench to Bedside
FEATURING
Kenneth Anderson
- 641 views
- July 1, 2024
- 5
Moffitt Cancer Center
Newly Diagnosed Myeloma: Why We Should Use a Response-Adapted Approach to Transplant
FEATURING
Kenneth Shain
- 230 views
- March 11, 2024
- 1
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "A Prospective Trial of Combining FDG-PET + Whole-Body MRI for Staging Newly Diagnosed and R/R Myeloma"
FEATURING
Claudio Cerchione
- 215 views
- June 7, 2024
- 1
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
MRD in the Era of Modern MM Therapies
FEATURING
Roberto Magalhaes
- 169 views
- February 15, 2024
Memorial Sloan Kettering Cancer Center
ASTCT Survey on Management of R/R Myeloma Patients After Failure by CAR-T
FEATURING
Hamza Hashmi
- 142 views
- May 21, 2024
- 1
Total Health
Myeloma Case Discussion: Newly Diagnosed Patient Achieving MRD- sCR After Induction
- 142 views
- February 29, 2024
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: PERSEUS Trial MRD Analysis: Dara + VRd in Transplant-Eligible NDMM
FEATURING
Pieter Sonneveld
- 95 views
- June 20, 2024
ecancer
ASCO® 2024 Insights: "Importance of MRD in Newly Diagnosed Multiple Myeloma"
FEATURING
Xavier Leleu
- 78 views
- July 18, 2024
- 1
Ola Landgren
A New System for Genomic Classification and Individualized Prognosis in NDMM
- 46 views
- March 5, 2024
ecancer
Management of Multiple Myeloma in a Resource-Constrained Setting
FEATURING
Henry Ddungu
- 39 views
- February 12, 2024
- 1
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Future Perspectives on the Management of Myeloma: Cure or Longterm Disease Control?
FEATURING
Roberto Magalhaes
- 38 views
- February 15, 2024
- 1
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Using AI in Medicine: Examples in MDS and Myeloma
FEATURING
Moshe Mittelman
- 35 views
- February 16, 2024
- 1
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Debates in Myeloma: Smoldering Myeloma Should NOT Be Treated
FEATURING
Evangelos Terpos
- 29 views
- February 15, 2024
- 1
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Case Discussion: Smoldering MM
FEATURING
Arda Bayar
- 14 views
- August 15, 2024
Disease Overview
Dana-Farber Cancer Institute
Multiple Myeloma 101: Diagnosis, Prognosis, and Risk
FEATURING
Paul Richardson
- 700 views
- July 2, 2024
- 5
Rush University Medical Center
High-Risk Myeloma: Updates in Defining and Managing
FEATURING
Jeffrey Zonder
- 133 views
- June 6, 2024
Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course
Multiple Myeloma: Not as Simple as "CRAB" Anymore
FEATURING
Rahul Banerjee
- 410 views
- August 14, 2024
- 4
Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course
Overview of Monoclonal Gammopathies From MGUS to Smoldering Myeloma
FEATURING
Mary Kwok
- 407 views
- August 14, 2024
- 2
University of Colorado Division of Hematology
Overview of Pathophysiology, Diagnosis and Management of Multiple Myeloma
FEATURING
Kelly Sidor
- 350 views
- October 24, 2023
- 2
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Management of Smoldering Myeloma
FEATURING
Claudio Cerchione
- 61 views
- August 27, 2024
- 1
Dana-Farber Cancer Institute
Updates in the Management of SMM/MGUS and the Prevention of Progression
FEATURING
Yuxin Liu
- 90 views
- July 2, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Comprehensive Review of 1L Therapy Approaches in MM
FEATURING
Alpay Yeşilaltay
- 11 views
- August 26, 2024
Louisville Hematology Highlights
Why Are Our Hematopoietic Stem Cells in the Bone Marrow?
FEATURING
Robert Peter Gale
- 3,478 views
- February 26, 2024
- 18
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Debates in Myeloma: Smoldering Myeloma Should Be Treated
FEATURING
Claudio Cerchione
- 26 views
- February 15, 2024
Case Studies
Winship Cancer Institute - Emory University
Multiple Myeloma: Clinical Challenges for the Community Clinician
FEATURING
Nisha Joseph
- 257 views
- April 16, 2024
- 3
PleXus Communications
Myeloma Rounds: Patient With SMM Enrolled in the DETER-SMM Trial
FEATURING
Nirav Antao
- 89 views
- November 27, 2023
Total Health
Myeloma Case Discussion: Newly Diagnosed Patient Achieving MRD- sCR After Induction
- 142 views
- February 29, 2024
Moffitt Cancer Center
Optimal Timing of CAR-T in Myeloma: Case-Based Discussion
FEATURING
Ciara Freeman
- 31 views
- March 7, 2024
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Case Presentation: R/R Myeloma With Extramedullary Plasmacytoma Involving Optic Chiasm
FEATURING
Alpay Yeşilaltay
- 13 views
- February 15, 2024
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
How I Manage Late Relapsed Myeloma With T-Cell Engaging Therapy
FEATURING
Alessandra Romano
- 14 views
- February 15, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Case Discussion: Smoldering MM
FEATURING
Arda Bayar
- 14 views
- August 15, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
A Case of MM With Atypical Cutaneous Presentation Treated With Dara and CyBorD
FEATURING
Bengisu Ece Duman
- 10 views
- August 15, 2024